Answers are grounded in this paper and cite their sources.
Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol, two commonly used analgesics. Methods This was an open‐label, fixed‐sequence, 2‐way crossover study in 13 healthy participants. On Day 1, 25 mg amitriptyline and 50 mg tramadol were co‐administered orally in a fasted condition, followed by a 7‐day washout period. On Day 8, 30 mg CBD was administered orally 1 h prior to amitriptyline and tramadol. Pharmacokinetic sampling was performed for CBD, amitriptyline, tramadol and their respective active metabolites nortriptyline and O‐desmethyltramadol for up to 24 h post‐dose. The areas under the curve (AUCs) were compared between visits using a mixed effects model. Results Twelve participants (4M/8F) completed the study; one participant (M) dropped out for personal reasons. CBD significantly increased the AUC 0‐24h (least square means [LSM] ratio 1.13, 95% CI: 1.01, 1.26, p = 0.033) and the C max (LSM ratio 1.17, 95% CI: 1.01, 1.36, p = 0.041 ) of amitriptyline. CBD did not significantly change the AUC 0‐24h and C max of nortriptyline and tramadol, and the C max of O‐desmethyltramadol. Conclusions A single dose of 30 mg CBD significantly influenced the metabolism of amitriptyline in healthy volunteers. In patients, CBD‐induced drug interactions may be more pronounced in chronic dosing and dependent upon prandial status.
No takes yet. Share an insight, caveat, or question.
Gorbenko et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: